GYNECOLOGY: GYNECOLOGIC ONCOLOGYLong-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer A Gynecologic Oncology Group StudyTewari, Devansu; Java, James J.; Salani, Ritu; Armstrong, Deborah K.; Markman, Maurie; Herzog, Thomas; Monk, Bradley J.; Chan, John K.Author Information Kaiser Permanente Irvine Medical Center, Irvine (D.T.); Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY (J.J.J.); Wexner Medical Center, Ohio State University, Columbus, OH (R.S.); Sidney Kimmel Comprehensive Cancer Center, John Hopkins University School of Medicine, Baltimore, MD (D.K.A.); Eastern Regional Medical Center, Cancer Treatment Centers of America, Philadelphia, PA (M.M.); University of Cincinnati, Cincinnati, OH (T.H.); Creighton University School of Medicine, Phoenix, AZ (B.J.M.); and California Pacific/Palo Alto Medical Foundation/Sutter Research Institute, San Francisco, CA (J.K.C.) Obstetrical & Gynecological Survey: August 2015 - Volume 70 - Issue 8 - p 505-506 doi: 10.1097/01.ogx.0000469913.56599.ae Buy Metrics Abstract Obstet Gynecol Surv 2015;70(8):505–506 The primary site of spread and failure in most cases of advanced epithelial ovarian carcinoma (EOC) is the peritoneum. Even in relapses, the disease is typically confined to the peritoneal cavity. Previous studies have found a 20-fold higher concentration of cisplatin in the peritoneum after intraperitoneal (IP) administration compared with that in plasma after intravenous (IV) administration. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.